Literature DB >> 24162151

Systemic involvement in primary Sjogren's syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry).

Manuel Ramos-Casals1, Pilar Brito-Zerón, Roser Solans, María-Teresa Camps, Arnau Casanovas, Bernardo Sopeña, Bernardino Díaz-López, Francisco-Javier Rascón, Rami Qanneta, Guadalupe Fraile, Roberto Pérez-Alvarez, José-Luis Callejas, Mar Ripoll, Blanca Pinilla, Miriam Akasbi, Eva Fonseca, Jesús Canora, María-Elvira Nadal, Gloria de la Red, Inés Fernández-Regal, Iratxe Jiménez-Heredia, Josep-Angel Bosch, María-del-Mar Ayala, Lluisa Morera-Morales, Brenda Maure, Arantxa Mera, Marc Ramentol, Soledad Retamozo, Belchin Kostov.   

Abstract

OBJECTIVE: To evaluate systemic involvement in primary SS in a large cohort of Spanish patients using the EULAR-SS disease activity index (ESSDAI) definitions.
METHODS: Systemic involvement was characterized using ESSDAI definitions for the 10 clinical domains (constitutional, lymphadenopathy, glandular, articular, cutaneous, pulmonary, renal, peripheral nervous system, central nervous system and muscular). ESSDAI scores at diagnosis, during follow-up and cumulated at the last visit were calculated.
RESULTS: The cohort consisted of 921 patients. After a mean follow-up of 75 months, 77 (8%) patients still had an ESSDAI score of zero at the last visit. Organ by organ, the percentage of patients who developed activity during the follow-up (ESSDAI score ≥ 1 at any time) ranged between 1.4% and 56%, with articular, pulmonary and peripheral neurological involvement being the most common. Logistic multivariate regression analysis showed the following features at diagnosis and had the closest association with systemic activity (statistically significant independent variables in at least two domains): cryoglobulinaemia in five domains; anaemia, lymphopenia and low C3 levels in three domains each and age <35 years in two domains. Sicca features, ANA and RF at diagnosis were not associated with a higher cumulated activity score in any clinical domain.
CONCLUSION: Primary SS is undeniably a systemic disease, with the joints, lungs, skin and peripheral nerves being the most frequently involved organs. Cytopenias, hypocomplementaemia and cryoglobulinaemia at diagnosis strongly correlated with higher cumulated ESSDAI scores in the clinical domains. Clinically the ESSDAI provides a reliable picture of systemic involvement in primary SS.

Entities:  

Keywords:  anti-Ro/SS-A antibodies; cryoglobulins; extraglandular involvement; hypocomplementemia; primary Sjögren’s syndrome

Mesh:

Year:  2013        PMID: 24162151     DOI: 10.1093/rheumatology/ket349

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  43 in total

1.  Sjögren's Syndrome is Associated With Reduced Lifetime Sex Hormone Exposure: A Case-Control Study.

Authors:  Sara S McCoy; Emmanuel Sampene; Alan N Baer
Journal:  Arthritis Care Res (Hoboken)       Date:  2019-06-24       Impact factor: 4.794

Review 2.  The Diagnosis and Treatment of Sjögren's Syndrome.

Authors:  Ana-Luisa Stefanski; Christian Tomiak; Uwe Pleyer; Thomas Dietrich; Gerd Rüdiger Burmester; Thomas Dörner
Journal:  Dtsch Arztebl Int       Date:  2017-05-26       Impact factor: 5.594

3.  Renal involvement in primary Sjogren's syndrome: a prospective cohort study.

Authors:  Ankit Jain; Bheemanathi Hanuman Srinivas; Dantis Emmanuel; Vikramraj K Jain; Sreejith Parameshwaran; Vir Singh Negi
Journal:  Rheumatol Int       Date:  2018-08-23       Impact factor: 2.631

4.  Development of new extra-glandular manifestations or associated auto-immune diseases after establishing the diagnosis of primary Sjögren's syndrome : A long-term study of the Antonius Nieuwegein Sjögren (ANS) cohort.

Authors:  E J Ter Borg; J C Kelder
Journal:  Rheumatol Int       Date:  2017-04-19       Impact factor: 2.631

5.  Transcultural adaptation of the EULAR activity index for primary Sjogren's syndrome in Argentine.

Authors:  Anastasia Secco; Lucila Marino; Natalia Herscovich; Pedro Aicardi; Lorena Techera; Lorena Takashima; María Lida Santiago; Felix Romanini; Marta Mamani; Antonio C Catalán Pellet
Journal:  Eur J Rheumatol       Date:  2019-12-16

6.  Eligibility for clinical trials in primary Sjögren's syndrome: lessons from the UK Primary Sjögren's Syndrome Registry.

Authors:  Clare Oni; Sheryl Mitchell; Katherine James; Wan-Fai Ng; Bridget Griffiths; Victoria Hindmarsh; Elizabeth Price; Colin T Pease; Paul Emery; Peter Lanyon; Adrian Jones; Michele Bombardieri; Nurhan Sutcliffe; Costantino Pitzalis; John Hunter; Monica Gupta; John McLaren; Annie Cooper; Marian Regan; Ian Giles; David Isenberg; Vadivelu Saravanan; David Coady; Bhaskar Dasgupta; Neil McHugh; Steven Young-Min; Robert Moots; Nagui Gendi; Mohammed Akil; Francesca Barone; Ben Fisher; Saaeha Rauz; Andrea Richards; Simon J Bowman
Journal:  Rheumatology (Oxford)       Date:  2015-10-27       Impact factor: 7.580

7.  Primary Sjögren's syndrome: Extraglandular manifestations and hydroxychloroquine therapy.

Authors:  J Demarchi; S Papasidero; M A Medina; D Klajn; R Chaparro Del Moral; O Rillo; V Martiré; G Crespo; A Secco; A Catalan Pellet; C Amitrano; C Crow; C Asnal; P Pucci; F Caeiro; N Benzanquen; J P Pirola; M Mayer; F Zazzetti; S Velez; J Barreira; N Tamborenea; L Santiago; L Raiti
Journal:  Clin Rheumatol       Date:  2017-09-14       Impact factor: 2.980

Review 8.  Renal involvement in primary Sjögren syndrome.

Authors:  Hélène François; Xavier Mariette
Journal:  Nat Rev Nephrol       Date:  2015-11-16       Impact factor: 28.314

Review 9.  Dysregulation of gut microbiome is linked to disease activity of rheumatic diseases.

Authors:  Yanfeng Bao; Chen Dong; Juan Ji; Zhifeng Gu
Journal:  Clin Rheumatol       Date:  2020-06-09       Impact factor: 2.980

10.  Persistent serological activity in primary Sjögren's syndrome.

Authors:  Jorge López-Morales; Daniel Cortes-Muñoz; Miguel Astudillo-Ángel; Gabriela Hernández-Molina
Journal:  Clin Rheumatol       Date:  2019-12-14       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.